chronic hepatitis c infection with a detectable hcv rna in the serum on two occasions, 6 months apart

focus hsv-2 igg negative and focus hsv-1 igg positive, using manufacturer's cut-offs

antiherpes or immunomodulatory therapy during the past 30 days,

hiv or chronic hepatitis b infection,

decompensated liver disease (ascites, hepatic encephalopathy, coagulopathy, jaundice/icterus),

creatinine clearance <50 ml/min.,

female subject who is pregnant or nursing,

gastrointestinal disorder which might result in malabsorption of valacyclovir,

history of erythema multiforme major, thrombotic thrombocytopenia purpura or hemolytic uremic syndrome,

allergy to valacyclovir or related drug.